Ajanta Pharma

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE031B01049
  • NSEID: AJANTPHARM
  • BSEID: 532331
INR
3,480.20
8.2 (0.24%)
BSENSE

Aug 07, 03:30 PM

BSE+NSE Vol: 37.71 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Part of MojoOne Strategy
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Ajanta Pharma
Gland Pharma
Emcure Pharma
Glenmark Pharma
Ipca Labs
Sai Life
Wockhardt
Anthem Bioscienc
Abbott India
Glaxosmi. Pharma
Piramal Pharma

Why is Ajanta Pharma Ltd. ?

1
High Management Efficiency with a high ROE of 22.14%
2
The company is Net-Debt Free
3
Positive results in Jun 26
  • NET SALES(Q) Highest at Rs 1,625.96 cr
  • PBDIT(Q) Highest at Rs 423.58 cr.
  • PBT LESS OI(Q) Highest at Rs 375.90 cr.
4
Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks
5
Market Beating performance in long term as well as near term
  • Along with generating 33.45% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report

Verdict Report

How much should you buy?

  1. Overall Portfolio exposure to Ajanta Pharma should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Ajanta Pharma for you?

Medium Risk, High Return

Absolute
Risk Adjusted
Volatility
Ajanta Pharma
33.05%
1.30
25.80%
Sensex
-2.63%
-0.19
13.57%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
14.23%
EBIT Growth (5y)
8.05%
EBIT to Interest (avg)
97.07
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.09
Sales to Capital Employed (avg)
1.10
Tax Ratio
24.00%
Dividend Payout Ratio
33.24%
Pledged Shares
22.53%
Institutional Holding
29.48%
ROCE (avg)
29.63%
ROE (avg)
22.14%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
38
Industry P/E
37
Price to Book Value
9.51
EV to EBIT
33.06
EV to EBITDA
29.08
EV to Capital Employed
10.35
EV to Sales
7.39
PEG Ratio
1.73
Dividend Yield
1.74%
ROCE (Latest)
29.63%
ROE (Latest)
23.33%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Bullish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

17What is working for the Company
NET SALES(Q)

Highest at Rs 1,625.96 cr

PBDIT(Q)

Highest at Rs 423.58 cr.

PBT LESS OI(Q)

Highest at Rs 375.90 cr.

PAT(Q)

Highest at Rs 334.22 cr.

EPS(Q)

Highest at Rs 26.66

-5What is not working for the Company
OPERATING CF(Y)

Lowest at Rs 529.19 Cr

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.94 times

Loading Valuation Snapshot...

Here's what is working for Ajanta Pharma

Net Sales - Quarterly
Highest at Rs 1,625.96 cr and Grown
each quarter in the last five quarters
MOJO Watch
Near term sales trend is very positive

Net Sales (Rs Cr)

Net Sales - Quarterly
At Rs 1,625.96 cr has Grown at 24.82%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 423.58 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 375.90 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 375.90 cr has Grown at 23.33%
Year on Year (YoY)
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 334.22 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 334.22 cr has Grown at 30.9%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 26.66
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Here's what is not working for Ajanta Pharma

Operating Cash Flow - Annually
Lowest at Rs 529.19 Cr
in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (Rs Cr)

Debtors Turnover Ratio- Half Yearly
Lowest at 2.94 times
in the last five half yearly periods
MOJO Watch
Company's pace of settling its Debtors has slowed

Debtors Turnover Ratio

Non Operating Income - Quarterly
Highest at Rs 70.90 cr
in the last five quarters
MOJO Watch
Increased income from non business activities may not be sustainable

Non Operating Income